Yongyan Bi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yongyan Bi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Cong Luo
Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China
1 shared publicationFulin Xu
Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China
1 shared publicationJie Ji
Department of Rehabilitation Medicine Minhang Hospital, Fudan University Shanghai China
1 shared publicationMingliang Chen
Research and Translational Laboratory of Acute Injury and Secondary Infection, Department of Laboratory Medicine Minhang Hospital, Fudan University Shanghai China
1 shared publication- Xiaoliu Li
Department of Rehabilitation Medicine Minhang Hospital, Fudan University Shanghai China
1 shared publication Ye Jiang
Department of Neurosurgery Minhang Hospital, Fudan University Shanghai China
1 shared publication
Latest Publications
- 14 April 2026
- Published by Wiley in Luminescence
- Vol. 41 (4) , e70480
Microbial‐Engineered Fluorescent Nanocarrier for Ion Ratiometric Sensing and sTREM‐1‐Mediated EBV Inhibition
Epstein–Barr virus (EBV), a widespread human γ‐herpesvirus, is associated with infectious mononucleosis and several malignancies, posing a major public health challenge. Acyclovir (ACV), the first‐line antiviral drug, is limited by poor solubility, short half‐life, and low bioavailability. To overcome these drawbacks, we designed a hyaluronic acid–based nanocarrier modified with microbial extracts and a fluorescent small molecule (1‐HA‐2), and constructed an ACV‐loaded nanosystem (1‐HA‐2@ACV) with improved drug loading, fluorescence responsiveness, and aqueous stability, enabling both therapeutic delivery and ion sensing. Notably, 1‐HA‐2@ACV allows sensitive detection of Na + and PO 4 3− , two clinically relevant ions whose dysregulation is closely linked to EBV‐associated disease progression, drug safety, and therapeutic monitoring. In EBV‐susceptible cells, EBV infection markedly increased EBNA1 and sTREM‐1 expression, whereas treatment with 1‐HA‐2@ACV significantly inhibited viral replication and reduced sTREM‐1 overexpression more effectively than free ACV, while blank nanoparticles showed no effect. These findings suggest that 1‐HA‐2@ACV not only enhances the therapeutic efficacy of ACV but also provides a dual‐function platform for EBV‐targeted therapy and real‐time monitoring through modulation of sTREM‐1 pathways and ion‐associated biomarkers.
- 14 April 2026
- Published by Wiley in Luminescence
- Vol. 41 (4) , e70480
Microbial‐Engineered Fluorescent Nanocarrier for Ion Ratiometric Sensing and sTREM‐1‐Mediated EBV Inhibition
Epstein–Barr virus (EBV), a widespread human γ‐herpesvirus, is associated with infectious mononucleosis and several malignancies, posing a major public health challenge. Acyclovir (ACV), the first‐line antiviral drug, is limited by poor solubility, short half‐life, and low bioavailability. To overcome these drawbacks, we designed a hyaluronic acid–based nanocarrier modified with microbial extracts and a fluorescent small molecule (1‐HA‐2), and constructed an ACV‐loaded nanosystem (1‐HA‐2@ACV) with improved drug loading, fluorescence responsiveness, and aqueous stability, enabling both therapeutic delivery and ion sensing. Notably, 1‐HA‐2@ACV allows sensitive detection of Na + and PO 4 3− , two clinically relevant ions whose dysregulation is closely linked to EBV‐associated disease progression, drug safety, and therapeutic monitoring. In EBV‐susceptible cells, EBV infection markedly increased EBNA1 and sTREM‐1 expression, whereas treatment with 1‐HA‐2@ACV significantly inhibited viral replication and reduced sTREM‐1 overexpression more effectively than free ACV, while blank nanoparticles showed no effect. These findings suggest that 1‐HA‐2@ACV not only enhances the therapeutic efficacy of ACV but also provides a dual‐function platform for EBV‐targeted therapy and real‐time monitoring through modulation of sTREM‐1 pathways and ion‐associated biomarkers.